ArticleCureus2025
Association of the Glycemia Risk Index With Glycemic Metrics and Sensor Usage in a Real-World Pediatric Population With Low Hypoglycemia Rates in Saudi Arabia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe Glycemia Risk Index (GRI) is a recently developed composite measure designed to consolidate overall glycemic control into a single, interpretable score. The aim of this study was to investigate the associations between the GRI and glycemic metrics derived from continuous glucose monitoring (CGM), including sensor usage time, in children with diabetes using the FreeStyle Libre 2 Plus® CGM system (Abbott Diabetes Care, Witney, UK).
methodDe-identified CGM data from 147 pediatric patients with diabetes in Saudi Arabia, treated at two governmental hospitals between January 2023 and September 2024, were analyzed. Glycemic metrics from the ambulatory glucose profile were recorded, and the GRI and its hypoglycemia and hyperglycemia components were calculated. Correlations between the GRI, its components, and time in range with glycemic metrics were assessed using Pearson and Spearman correlation coefficients. The associations between GRI and its components and two sensor usage time groups (70%-89% versus >90%) were evaluated using the independent t-test and Mann-Whitney U test. A p-value < 0.05 was considered statistically significant.
resultsThere was a negative correlation between GRI and time in range (r = -0.941), level one time above range (181-250 mg/dl; r = -0.447), time below range (< 70 mg/dl; r = -0.244), level one time below range (69-54 mg/dl; r = -0.248), and hypoglycemia component (r = -0.243) (all p-values <0.05). There was a positive correlation between GRI and average blood glucose (r = 0.923), glucose management indicator (r = 0.922), time above range (>180 mg/dl; r = 0.893), level two time above range (>250 mg/dl; r = 0.944), and hyperglycemia component (r = 0.929) (all p-values <0.05). Participants with lower sensor usage (70-89%) had significantly higher GRI values (median: 96.00; IQR: 75.80-100.00) compared to those with ≥90% usage (median: 82.40; IQR: 60.40-100.00; p = 0.004). The hyperglycemia component was also significantly higher in the lower usage group (mean: 53.65 vs. 46.62, p = 0.032).
conclusionAverage glucose, glucose management indicator, and time in range showed negative correlations with GRI, while extreme hyperglycemia correlated positively. These results support GRI's role in assessing hyperglycemic exposure and treatment efficacy. Unexpected negative correlations with mild hyperglycemia and mild hypoglycemia warrant further studies. GRI and its hyperglycemic component improved with increased sensor usage, suggesting better glycemic control with higher CGM adherence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.